Atheromatosis extent in coronary artery disease is not correlated with apolipoprotein-E polymorphism and its plasma levels, but associated with cognitive decline

Current Alzheimer Research

Volumn 7, Issue 6, 2010, Pages 556-563

  Lima, L M ^a,b   Carvalho, M d G ^a   Ferreira, C N ^a   Fernandes, A P ^a   Neto, C P d F ^c   Garcia, J C F ^c   Reis, H J ^a   Janka, Z ^d   Palotas A ^e   Sousa, M d O ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital Geral Socor   (Brazil)

^d UNIVERSITY OF SZEGED   (Hungary)

^e Asklepios Med Bt   (Hungary)

Author keywords

Alzheimer's disease; Apolipoprotein E; Atheromatosis; Cognitive impairment; Coronary artery disease; Plasma levels; Polymorphism

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMATOSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

ADULT; AGED; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; COGNITION DISORDERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLAQUE, ATHEROSCLEROTIC; POLYMORPHISM, GENETIC;

EID: 78549285952     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510792231711     Document Type: Article

References (41)

1. Manzano S, González JL, Marcos A, Matías-Guiu J. Genetics and Alzheimer's disease. Neurologia 24 (2): 83-89 (2009).
2. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a huge review. Am J Epidem 155: 487-495 (2002).
3. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sciences 31: 445-454 (2006).
4. Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann N Y Acad Sci USA 826: 128-146 (1997).
5. Kosunen O, Talasniemi S, Lehtovirta M, Heinonen O, Helisalmi S, Mannermaa A, et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke 26 (5): 743-748 (1995).
6. Baroni MG, Berni A, Romeo S, Arca M, Tesorio T, Sorropago G, et al. Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. BMC Medical Genetics 4: 962-968 (2003).
7. Siest G, Pillot T, Régis-Bailly A, Leininger-Müller B, Steinmetz J, Galteau MM. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 41: 1068-1086 (1995).
8. Schwanke CHA, DaCruz IBM, Leal NF, Scheibe R, Moriguchi Y, Moriguchi EH. Analysis of the association between apolipoprotein E polymorphism and cardiovasclar risk factors in an elderly population with longevity. Arq Bras Cardiol 78: 571-579 (2002).
9. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141: 137-147 (2004).
10. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8: 1-21 (1988).
11. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodrigues C, Park JS, Cole T, et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113: 157-166 (1995).
12. Sousa MO, Alía P, Pintó X, Corbella E and Navarro M-A. Interaction between ApoA5-1131T>C and ApoE polymorphisms and their association with severe hypertriglyceridemia. Clin Chim Acta 395: 68-71 (2008).
13. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahbolm A, et al. Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk. JAMA 298: 1300-1311 (2007).
14. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T. The presence of apolipoprotein ε4 and ε 2 alleles augments the risk of coronary artery disease in type 2 diabetic. Clin Biochem 40: 1150-1156 (2007).
15. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglycerides levels by apoE phenotype: a meta-analysis. Lipid Res 33: 447-454 (1992).
16. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 152: 475-488 (2000).
17. Friedewald WT, Levy RI, Fredrickison DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifugue. Clin Chem 18: 499-552 (1972).
18. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, et al. Determination by PCR-RFLP of apo E genotype in a japanese population. J Lab Clin Med 121 (4): 598-602 (1992).
19. Armitage P, Berry G. Statistical methods in medical research. Blackwell Science, p396 (1994).
20. Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 91: 265-269 (1995).
21. Stengard JH, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Genotypes with the apolipoprotein ε-4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men aged 65-84 years. Hum Genet 97: 677-684 (1996).
22. Granér M, Kahri J, Varpula M, Salonen RM, Nyyssönen K, Jauhiainen M, et al. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 18: 271-277 (2008).
23. Mendes-Lana A, Pena GG, Freitas SN, Lima AA, Nicolato RLC, Nascimento-Neto RM, Machado-Coelho GLL, et al. Apolipoprotein E polymorphism in Brazilian dyslipidemic individuals: Ouro Preto Study. Braz J Med Biol Res 40 (1): 49-56 (2007).
24. Fiegenbaum M, de Andrade FM, Hutz MH. Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: Effect of gender, smoking and APOE genotypes. Clin Chim Acta 380: 175-181 (2007).
25. De França E, Alves JG, Hutz MH. Apolipoprotein E polymorphism and its association with serum lipid levels in Brazilian children. Hum Biol 76 (2): 267-275 (2004).
26. Souza DRS, Nakachima L, Biagioni RB, Nakazone MA, Pinhel MAS, Trindade DM, et al. Relevance of apolipoprotein E4 for the lipid profile of Brazilian patients with coronary artery disease. Braz J Med Biol Res 40: 189-197 (2007).
27. Hallman DM, Boerwinkle E, Sasha N, Sandholzer C, Menzel HJ, Csazar A, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49: 338-349 (1991).
28. Tarchalski J, Guzik P, Wysocki H. Correlation between the extent of coronary atherosclerosis and lipid profile. Mol Cell Biochem 246: 25-30 (2003).
29. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 25: 436-441 (2005).
30. Singh PP, Singh M, Bhatnagar DP, Kaur TP, Gaur SK. Apolipoprotein E polymorphism and its relation to plasma lipids in coronary artery disease. Indian J Med Sci 62 (3): 105-112 (2008).
31. Bertolini S, Pisciotta L, Di Scala L, Langheim S, Bellocchio A, Masturzo P, et al. Genetic polymorphisms affecting the phenotypic expression of familial hypercholesterolemia. Atherosclerosis 174 (1): 57-65 (2004).
32. Tavintharan S, Lim SC, Chan YH, Sum CF. Apolipoprotein E genotypes affect the response to lipid-lowering therapy in Chinese with type 2 diabetes mellitus. Diabetes Obes Metab 9: 81-86 (2006).
33. Sousa MO, Corbella E, Alía P, Cámara J, Castro MJ, Pintó X, et al. Lack of association between the APOE genotype and the response to statin treatment in patients with acute ischemic episodes. Med Clin (Barc) 29: 401-404 (2008).
34. Ferreira CN, Carvalho MG, Fernandes AP, Lima LM, Loures-Valle AA, Dantas J, et al. Comparative study of apolipoprotein-E polymorphism and plasma lipid levels in dyslipidemic and asymptomatic subjects, and their implication in cardio/cerebro-vascular disorders. Neurochem Int 56: 177-182 (2010).
35. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158: 183-193 (2001).
36. Perlmutter L, Chui CH. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 24: 677-786 (1990).
37. Alafuzoff I, Helisalmi S, Mannermaa A, Soininen H. Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in aging and dementia. Ann N Y Acad Sci USA 903: 244-251 (2000).
38. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 11: 601-607 (1990).
39. Abe K, Tanzi RE, Kogure K. Selective induction of Kunitz-type protease inhibitor domain containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci Lett 125: 172-174 (1991).
40. Vincent-Viry M, Schiele F, Guegen R, Ohnet K, Visvikis S, Siest G. Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the Stanislas cohort study. Clin Chem 44: 957-965 (1998).
41. Palotás A. I have forgotten ever having undergone heart surgery. Pharmacogenomics J. 8: 1-3 (2007).